Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Down 18.1% in April

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 2,210,000 shares, a drop of 18.1% from the March 31st total of 2,700,000 shares. Approximately 4.8% of the company’s shares are short sold. Based on an average daily volume of 909,000 shares, the short-interest ratio is currently 2.4 days.

Wall Street Analyst Weigh In

PYXS has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, April 10th. BTIG Research initiated coverage on shares of Pyxis Oncology in a research report on Friday, February 9th. They issued a “buy” rating and a $8.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd. SVB Leerink began coverage on Pyxis Oncology in a research note on Tuesday, January 23rd. They issued an “outperform” rating and a $12.00 price objective on the stock. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of Pyxis Oncology in a report on Tuesday, January 23rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $8.50.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS traded up $0.14 during trading hours on Monday, reaching $4.44. The stock had a trading volume of 478,255 shares, compared to its average volume of 778,143. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85. The firm’s 50 day moving average is $5.08 and its 200-day moving average is $3.28. The stock has a market capitalization of $258.10 million, a price-to-earnings ratio of -2.41 and a beta of 1.52.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Thursday, March 21st. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.16. Analysts forecast that Pyxis Oncology will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. abrdn plc purchased a new position in shares of Pyxis Oncology during the fourth quarter worth about $1,275,000. Vestal Point Capital LP purchased a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $792,000. Decheng Capital LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $588,000. Decheng Capital Management III Cayman LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth approximately $650,000. Finally, Cable Car Capital LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $111,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.